Company intelligence / Profile preview
Aurora Biopharma
- Ownership
- Private
- Development stage
- Phase 1
Overview
Aurora Biopharma develops autologous CAR-T therapies targeting HER2 for resistant solid tumors. Completed two clinical trials with promising safety and efficacy signals in glioblastoma and sarcoma. Ongoing/recruiting studies include osteosarcoma and recurrent glioblastoma. Early results show strong tumor-killing activity, survival benefits, and objective response rates above historical controls.
- Therapeutic areas
- Oncology
- Modalities
- Autologous CAR-T cell therapyCancer immunotherapy (adoptive cell transfer)Chimeric Antigen Receptor T-cell therapy (CAR T)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Aurora Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurora Biopharma.